<DOC>
	<DOCNO>NCT02001233</DOCNO>
	<brief_summary>The purpose follow-up study evaluate two-year efficacy , immunogenicity safety EV71 Vaccines prevent Hand , Foot Mouth disease cause EV71 total 10,000 healthy infant volunteer age 6 35months old .</brief_summary>
	<brief_title>A Follow-up Study Phase III , Efficacy Trial Inactivated Enterovirus Type 71 ( EV71 ) Vaccine</brief_title>
	<detailed_description>The phase III , efficacy trial inactivate vaccine ( vero cell ) EV71 complete March 2013 China . The data phase III study suggest inactivated EV71 vaccine protection effect healthy Chinese infant Hand , Foot Mouth disease cause EV71 within one-year surveillance period , clinically acceptable safety good one-year immune persistence . This study phase III , open-labelled , follow-up research , order evaluate two-year efficacy , safety immune persistence .</detailed_description>
	<mesh_term>Mouth Diseases</mesh_term>
	<mesh_term>Enterovirus Infections</mesh_term>
	<mesh_term>Foot-and-Mouth Disease</mesh_term>
	<mesh_term>Hand , Foot Mouth Disease</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>All subject vaccinate least one injection EV71 vaccine placebo phase III efficacy trial . subject refuse continue study .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>35 Months</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>EV71 vaccine</keyword>
	<keyword>EV71-associated HFMD</keyword>
	<keyword>efficacy</keyword>
	<keyword>safety</keyword>
	<keyword>immune persistence</keyword>
</DOC>